ARCA biopharma (ABIO) Receives Media Impact Score of 0.26
News stories about ARCA biopharma (NASDAQ:ABIO) have trended positive on Sunday, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ARCA biopharma earned a news impact score of 0.26 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.3802932793582 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of ARCA biopharma (NASDAQ ABIO) opened at $1.45 on Friday. ARCA biopharma has a 52-week low of $1.05 and a 52-week high of $3.00.
ARCA biopharma (NASDAQ:ABIO) last posted its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.39) EPS for the quarter.
ARCA biopharma, Inc (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF).
Receive News & Stock Ratings for ARCA biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARCA biopharma Inc. and related stocks with our FREE daily email newsletter.